Walmart says it has seen impact on shopping demand of diabetes drugs Ozempic, Wegovy and others Appetite suppressing drugs.
“We do see a slight change compared to the overall population, we do see a slight pullback in the overall basket,” John Furner, chief executive of Walmart’s massive U.S. operations, said in an interview Wednesday. “Fewer units and slightly fewer calories.”
The Bentonville, Arkansas-based retailer is using anonymous data on its shopper base to study changes in sales patterns. It can look at changes in purchases by people who take the drug and also compare those habits to similar people who don’t take the drug. Furner said it was too early to draw any firm conclusions about appetite suppressants and similar drugs made by Novo Nordisk.
More and more CEOs and investor is talking about how a popular weight-loss drug might change the economy and business.Earlier this week, the CEO of the maker of Pringles and Cheez-Its said the company was study Their potential impact on eating behavior.
“Like anything that could impact our business, we look at it, study it and mitigate it where necessary,” Kellanova Chief Executive Steve Cahillane said in an interview.
Walmart sells GLP-1 drugs through its pharmacies, a category that includes Ozempic. In August, the company said they were driving revenue growth for retailers. According to a recent report, U.S. sales of these drugs grew by 300% between 2020 and 2022 Report From Trilliant Health.
“We continue to expect food, consumer goods and health and wellness to grow in the second half, primarily due to some GLP – 1 The popularity of the drug will be a percentage of total volume.”
Svlook
